Chemotherapy, radiation, and immunotherapy before surgery for low rectal cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy given before surgery for low rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients with a specific type of cancer that is microsatellite stable (MSS).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal adenocarcinoma (a type of rectal cancer).
- Your tumor is low in the rectum and has not spread to other parts of the body.
- Your cancer is MSS (microsatellite stable), which means a specific genetic test shows it is not the MSI-high type.
- You are in generally good health, able to care for yourself, and have adequate organ function as shown by blood tests.
- You have not had surgery or emergency treatment for serious bowel problems like blockage, perforation, or severe bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, internal radiation (brachytherapy), and several drugs to shrink rectal cancer before surgery. The goal is to improve outcomes and potentially avoid more extensive surgery.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests combining standard chemotherapy and radiation with an immunotherapy drug (QL1706) before surgery for low rectal cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests giving chemotherapy and radiation before surgery to people with advanced rectal cancer that is low in the rectum. The goal is to shrink the tumor enough to allow the surgeon to save the sphincter (the muscle that keeps you from leaking stool), so you might avoid a permanent colostomy bag.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Hear when a new MSS-type Low Rectal Cancer，Neoadjuvant Chemoradiotherapy, QL1706 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.